Navigation Links
CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Date:1/19/2008

ATLANTA, Jan. 20 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU002 )

Corrado Tamburino, MD, President of the Italian Society of Interventional Cardiology, Chief of Interventional Cardiology at Ferrarotto Hospital and Full Professor of Cardiology at the University of Catania is Principal Investigator for the ATLANTA study. Dr. Tamburino noted, "I perform many angioplasties in each single day, many, and I am totally impressed by the performance of this stent in a very complex patient population. No thrombosis. Low binary restenosis. No MIs. This may be an answer to the problems we are facing with other stent systems."

The CATANIA(TM) Stent System with NanoThin Polyzene(R)-F, dubbed "The CAT" by cardiologists who have used the product, has completed CE Marking and is available for sale anywhere the CE Mark is accepted. Advantages include:

-- Early and complete vessel healing, as early as 30 days.

-- Patients can discontinue dual anti-platelet therapy after only one

month.

-- Protection from stent thrombosis

-- The Polyzene(R)-F surface treatment is bacterial-resistant

"The FDA has cautioned physicians about a small but significant increased risk of stent thrombosis for patients with drug-eluting stents. Now, Britain's National Institute for Health and Clinical Excellence is considering restrictions on DES because they are not cost-effective for most patients and because of uncertainties about safety. Polyzene(R)-F seems to solicit a positive biological response that treats the stent as accepted part of the vessel. As a result, 'The CAT' patients have excellent outcomes and can be free from the medical complications and financial burden associated with indefinite anti-platelet therapy," stated Thomas A. Gordy, President and Chief Executive Officer.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com.

Contact:

Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017  Kratom leaves, from a ... are often used to prepare tea-like beverages and ... million Americans annually to increase alertness, enhance well-being ... for minor aches and pains. PinneyAssociates, review of ... to assist FDA and DEA in determining the ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017  Hoy, ... lanzaron Access Accelerated, una iniciativa global para avanzar el ... y atención en países de renta baja y baja-media ... alcanzado un punto de crisis, particularmente en países de ... 80 por ciento de las muertes relacionadas con NCD. ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
(Date:1/19/2017)... ... 2017 , ... The CHP suggests that California drivers can avoid hydroplaning as ... and increasing the space between themselves and other vehicles, according to a January 3 ... R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today ... implement new sales and marketing strategies. Grover comes with a total of 15 years ... a half years as Executive Vice President of Direct Sales at Traeger® Wood Pellet ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for ... people know that popular cosmetic fillers can enhance earlobes and rejuvenate ... director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. ...
Breaking Medicine News(10 mins):